Article
Baltimore-Divergence and convergence abnormalities are similar in nature and can be difficult to differentiate. Michael Repka, MD, described the subtleties as well as what works best for these patients.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial